isis 416858
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01713361)
Timeline
Indications
Mechanism of action
- Coagulation factor XIAGONIST
F11 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 416858
- isis-fxi
- isis-fxirx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03582462 | Phase 1 | Jul 9, 2018 | Ionis Pharmaceuticals, Inc. |
| NCT03358030 | Phase 2 | Dec 1, 2017 | Bayer, Ionis Pharmaceuticals, Inc. |
| NCT02553889 | Phase 2 | Oct 1, 2015 | Bayer, Ionis Pharmaceuticals, Inc. |
| NCT01713361 | Phase 2 | Oct 1, 2012 | Ionis Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2012 |
| Bayer | For profit | 2 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1